- Report
- April 2023
- 124 Pages
Global
From €4554EUR$4,750USD£3,805GBP
- Report
- September 2024
- 82 Pages
Japan
From €3355EUR$3,500USD£2,804GBP
- Report
- November 2021
- 119 Pages
Global
From €4314EUR$4,500USD£3,605GBP
- Report
- November 2023
- 293 Pages
Global
€4789EUR$4,995USD£4,001GBP
- Report
- July 2024
- 105 Pages
Global
From €3500EUR$3,911USD£3,027GBP
- Report
- August 2024
- 84 Pages
Global
From €3500EUR$3,911USD£3,027GBP
- Report
- June 2023
- 95 Pages
Global
From €3500EUR$3,911USD£3,027GBP
The Prostate Specific Antigen (PSA) market is a segment of the Diagnostics industry that focuses on the detection of prostate cancer. PSA tests measure the amount of PSA in a patient's blood, which can be an indicator of prostate cancer. PSA tests are typically used in conjunction with other tests, such as digital rectal exams, to diagnose prostate cancer. PSA tests are also used to monitor the progression of prostate cancer in patients who have already been diagnosed.
The PSA market is highly competitive, with a number of companies offering PSA tests. Some of the major players in the market include Abbott Laboratories, Siemens Healthineers, Roche Diagnostics, and Beckman Coulter. Other companies in the market include Becton Dickinson, Ortho Clinical Diagnostics, and Sysmex Corporation. Show Less Read more